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PXPEDITED REVIEW
Randomized Trial of Circumferential
ulmonary Vein Ablation Versus Antiarrhythmic
rug Therapy in Paroxysmal Atrial Fibrillation
he APAF Study
arlo Pappone, MD, PHD, FACC,* Giuseppe Augello, MD,* Simone Sala, MD,*
ilippo Gugliotta, BENG,* Gabriele Vicedomini, MD,* Simone Gulletta, MD,* Gabriele Paglino, MD,*
atrizio Mazzone, MD,* Nicoleta Sora, MD,* Isabelle Greiss, MD,* Andreina Santagostino, MD,*
aura LiVolsi, MD,* Nicola Pappone, MD,† Andrea Radinovic, MD,* Francesco Manguso, MD, PHD,*
incenzo Santinelli, MD*
ilan and Telese Terme, Italy
OBJECTIVES We compared ablation strategy with antiarrhythmic drug therapy (ADT) in patients with
paroxysmal atrial fibrillation (PAF).
BACKGROUND Atrial fibrillation (AF) ablation strategy is superior to ADT in patients with an initial history
of PAF, but its role in patients with a long history of AF as compared with ADT remains a
challenge.
METHODS One hundred ninety-eight patients (age, 56  10 years) with PAF of 6  5 years’ duration
(mean AF episodes 3.4/month) who had failed ADT were randomized to AF ablation by
circumferential pulmonary vein ablation (CPVA) or to the maximum tolerable doses of
another ADT, which included flecainide, sotalol, and amiodarone. Crossover to CPVA was
allowed after 3 months of ADT.
RESULTS By Kaplan-Meier analysis, 86% of patients in the CPVA group and 22% of those in the ADT
group who did not require a second ADT were free from recurrent atrial tachyarrhythmias
(AT) (p  0.001); a repeat ablation was performed in 9% of patients in the CPVA group for
recurrent AF (6%) or atrial tachycardia (3%). At 1 year, 93% and 35% of the CPVA and ADT
groups, respectively, were AT-free. Ejection fraction, hypertension, and age independently
predicted AF recurrences in the ADT group. Circumferential pulmonary vein ablation was
associated with fewer cardiovascular hospitalizations (p  0.01). One transient ischemic
attack and 1 pericardial effusion occurred in the CPVA group; side effects of ADT were
observed in 23 patients.
CONCLUSIONS Circumferential pulmonary vein ablation is more successful than ADT for prevention of PAF
with few complications. Atrial fibrillation ablation warrants consideration in selected patients
in whom ADT had already failed and maintenance of sinus rhythm is desired. (A Controlled
Randomized Trial of CPVA Versus Antiarrhythmic Drug Therapy in for Paroxysmal AF:
APAF/01; http://clinicaltrials.gov/ct/show; NCT00340314) (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.0372340–7) © 2006 by the American College of Cardiology Foundation
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Currently, antiarrhythmic drug therapy (ADT) is consid-
red as first line therapy to prevent recurrent and symptom-
tic atrial fibrillation (AF), but antiarrhythmic drugs
AADs) are frequently ineffective and may be associated
ith serious adverse effects (1–3). Atrial fibrillation ablation
as been demonstrated to be effective in patients with AF
nd may be a realistic alternative to chronic ADT (4–10).
ecently, it has been reported in 3 randomized trials the
triking superiority of AF ablation strategy over ADT
11–13). The first study by Wazni et al. (11) was a pilot
From the Division of Cardiac Pacing and Electrophysiology, San Raffaele
niversity Hospital, Milan, Italy; and the †Salvatore Maugeri Foundation, IRCCS,
elese Terme, Italy.i
Manuscript received August 2, 2006; revised manuscript received August 23, 2006,
ccepted August 28, 2006.tudy that confined the analysis to untreated patients with
n initial history of paroxysmal AF (PAF), who represent
nly a minority of the wide AF population. In another
andomized study, Stabile et al. (12) reported that ablation
herapy combined with ADT was superior to ADT alone in
atients with paroxysmal or persistent AF. Recently, we
emonstrated that circumferential pulmonary vein ablation
CPVA) is more effective than amiodarone in maintaining
inus rhythm (SR) at 1 year, even in patients with perma-
ent AF (13). Whether CPVA alone is superior to ADT in
atients with PAF is still unknown. Thus, we conducted a
andomized controlled trial (the APAF [Ablation for Par-
xysmal Atrial Fibrillation] trial) to determine whether
PVA was superior to ADT for maintaining SR at 1 yearn patients with a long history of PAF.
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tudy design. This study was designed to compare the
elative efficacy of CPVA and ADT in the treatment of
atients with PAF who have already failed AADs. Patients
ere randomized to another 3 widely used AADs (amioda-
one, flecainide, or sotalol, either as single drugs or in
ombination) at the maximum tolerable doses (Fig. 1). All
onsecutive patients with PAF referred to our electrophys-
ology lab at the San Raffaele University Hospital starting
rom January 2005 were screened for inclusion and exclusion
riteria (Table 1). At time of enrollment, patients were
andomized to 1 of 2 treatment arms: CPVA or long-term
DT (Fig. 1). The 198th patient was enrolled on May 11,
005. All patients signed a written informed consent, which
as first approved by the institutional ethics and review
oard committees of the San Raffaele University Hospital.
PVA therapy. The details of the CPVA procedure have
een previously described (4,5,14,15). Left atrial geometry
as constructed with either CARTO (Biosense-Webster,
Abbreviations and Acronyms
AAD  antiarrhythmic drug
ADT  antiarrhythmic drug therapy
AF  atrial fibrillation
AT  atrial tachyarrhythmia
CPVA  circumferential pulmonary vein ablation
EF  ejection fraction
PAF  paroxysmal atrial fibrillation
SR  sinus rhythm
igure 1. Study design. Enrolled patients were randomized to circumfer-
ntial pulmonary vein ablation (CPVA) (n  99) or antiarrhythmic drug
herapy (ADT) (n  99). After 4 weeks of antiarrhythmic therapy (run-ina
hase), patients proceeded to the randomized treatment (i.e., catheter
blation or solely continuing ADT). AAD  antiarrhythmic drug.iamond Bar, California) or NavX (Endocardial Solutions
nc., St. Paul, Minnesota) (Fig. 2). Radiofrequency appli-
ations were done with either an 8-mm standard catheter
Navi-Star, Biosense-Webster or Livewire TC, St. Jude
edical, St. Paul, Minnesota) or an irrigated tip catheter
3.5-mm Cool-Path, St. Jude Medical or Thermo-Cool
avi-Star, Biosense-Webster); radiofrequency settings were
0 to 100 W, 50 to 65°C and 25 to 40 W, 35 to 40°C,
espectively. Completeness across mitral isthmus lines was
ssessed as previously described (15). Ablation at the
avotricuspid isthmus to prevent isthmus-dependent atrial
utter was performed in all patients. To reduce the proba-
ility of early recurrences of AF that could interfere with the
everse remodeling process, patients were treated with ADT
or 6 weeks after catheter ablation; thereafter, a 12-month
ollow-up started (Fig. 1). If there was a recurrence of atrial
achyarrhythmias (AT) (including both AF and atrial tachy-
ardia) beyond the first 6 weeks after the ablation, then a
e-do procedure could be performed if the patient wished to
roceed.
DT. Oral flecainide was given at an initial dose of 100 mg
very 12 h, oral sotalol at an initial dose of 80 mg every 8 h,
nd oral amiodarone at an initial loading of 600 mg/day for
he first week, 400 mg/day for the next week, after which a
aily maintenance dose of 200 mg a day was given. The
aximum tolerable dosage (up to 300 mg/day for flecainide
nd 320 mg/day for sotalol) was based on the clinical
esponse and/or the occurrence of side effects. Doses of each
rug were reduced if intolerable adverse reactions occurred,
able 1. Exclusion and Inclusion Criteria
nclusion criteria
Age 18 or 70 yrs
Creatinine concentration 1.5 mg/dl
AF history 6 months
AF burden 2 episodes/month in the last 6 months*
xclusion criteria
AF secondary to transient or correctable abnormality
Intra-atrial thrombus, tumor precluding catheter insertion
LA diameter 65 mm
Left ventricular ejection fraction 35%
HF symptoms  NYHA functional class II
Prior ADT therapy with amiodarone, flecainide, and sotalol
Contraindication to beta-blocking therapy
Patients with rheumatic mitral valve disease
Unstable angina or acute or prior myocardial infarction (6 months)
Wolff-Parkinson-White syndrome
Renal or hepatic failure
Implanted device (pacemaker or cardioverter-defibrillator)
Need for antiarrhythmic therapy for arrhythmias other than AF
Contraindication to ADT† or anticoagulation with warfarin
History of a cerebrovascular accident
Prior attempt at catheter or surgical ablation for AF
The AF burden was quantified before enrolment by review of patient charts.
Thyroid dysfunction, interstitial lung disease with DLCO 70% of predicted or
evere asthma, QT interval exceeding 400 ms, symptomatic sinus node or atrioven-
ricular node dysfunction unless a pacemaker is implanted, or evidence of stress-
nduced myocardial ischemia.
ADT  antiarrhythmic drug therapy; AF  atrial fibrillation; DLCO  diffusion
apacity of the lung for carbon monoxide; HF  heart failure; LA  left atrial;
YHA  New York Heart Association.nd treatment was stopped if they persisted. Even with AF
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CPVA Versus Drug Therapy in Paroxysmal AF December 5, 2006:2340–7ecurrences, the patient could be maintained on the same
rug and dose regimen if the investigator determined that
n acceptable clinical response was achieved based on the
uration and/or frequency of previous arrhythmia recur-
ences. In case of failure of the first assigned drug at the
aximum tolerable dosage, the choice of a second drug trial
as left to the primary physician, to be chosen from the
ther 2 antiarrhythmic agents or a combination of 2 of the
agents used in this study; the minimum period after which
he second ADT trial was considered unsuccessful was set at
months. After 2 trials of ADT, patients could be consid-
red for crossover to CPVA (Fig. 1).
nticoagulant therapy. All patients were anticoagulated
ith warfarin to maintain an international normalized ratio
f 2.0 to 3.0. Anticoagulation was discontinued if SR was
aintained for 6 weeks without any episodes of symp-
omatic or asymptomatic AF and in the absence of concur-
ent indications.
ollow-up. All patients were seen in an outpatient clinic
uring the initial screening period before randomization and
t 3, 6, and 12 months after randomization. At each visit,
2-lead electrocardiogram (ECG), 48-h Holter monitoring,
nd a transthoracic echocardiogram were obtained. Three
onths after randomization, thyroid function tests, hepatic
anel, and serum chemical measurements were obtained.
hest X-ray and potential corneal deposits were also eval-
ated in patients receiving long-term amiodarone therapy.
ll patients were provided with an event monitor (Life
atch, Buffalo Grove, Illinois) and were asked to record
heir rhythm 1 to 3 times daily and whenever they experi-
Figure 2. Pre- and post-ablation bipolar voltage maps of the lenced symptoms suggestive of AT. All 1-min rhythm aracings and echocardiograms were interpreted by 2 physi-
ians blinded to the patient randomized arm. In the event of
isagreement, the final interpretation was left to one of the
uthors, who were unaware of which group the patient
elonged. An arrhythmia had to last 5 s. Rhythm trans-
issions were available from all patients for 94  2% days
f follow-up.
nd point. The primary end point of this study was
reedom from documented recurrent AT during a 12-
onth follow-up in patients who underwent CPVA and in
hose receiving ADT. The end point was reached with the
rst episode of AT, and cases with a second ADT or repeat
blation procedure were considered failures. Recurrence of
T was defined as AT that lasted at least 30 s (5).
Monthly rhythm analysis according to different mapping
ystems and different catheters as well as number of hospi-
alizations and complications in both groups were also
nalyzed.
tatistical analysis. Based on a conservative assumption
hat SR would be maintained at 1 year in at least 75% of
atients in the CPVA group (4,5) and 50% of patients in the
ontrol group (16), a minimum of 85 patients was required
n each group at a power of 90% to reach a 2-tailed alpha of
.05. Considering the possibility of drop-outs, we planned
o increase the number of patients by 15% for each group.
ata are expressed as mean values SD and analyzed using
he intention-to-treat method. Continuous variables were
ompared by independent samples t test after checking with
evene’s test for equality of variances and with the paired
amples t test, when appropriate. Categorical variables were
um with either CARTO (A) or NavX systems (B) are shown.nalyzed by chi-square test. Multivariate Cox regression
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December 5, 2006:2340–7 CPVA Versus Drug Therapy in Paroxysmal AFnalysis was performed to determine the clinical predictors
f freedom from recurrent AF. Observed event-free survival
urves for both groups—presented as Kaplan-Meier plots—
ere compared among them by 2-sample log-rank tests.
value of p  0.05 indicated statistical significance. SPSS
4.0.2 (SPSS Inc., Chicago, Illinois) was used for the
tatistical analysis. The prevalence of SR and AT during
ollow-up were also reported and compared on a monthly
asis. One rhythm recording in AT in a given month was
ufficient to classify the patient as having suffered from AT
n that month.
ESULTS
tudy population. Among 334 screened patients, 198 were
nrolled in the study and underwent randomization (Fig. 1).
he most frequent reasons for the failure to enroll screened
atients were previous ADT over the last 24 months with
miodarone (46 patients), flecainide (35 patients), and
otalol (25 patients) or combination of them (22 patients).
haracteristics of the 2 randomized groups are shown in
able 2. Most enrolled patients had received previous
reatment with propafenone, dysopiramide, and quinidine
s single agents (140 patients) or in combination of digoxin
nd verapamil (58 patients).
blation group. Circumferential pulmonary vein ablation
as performed in 99 patients with a mean of 35  12 min
f radiofrequency energy. The mean CPVA procedure time
as 81  31 min. Inferior vena cava-tricuspid annulus
sthmus bidirectional block was successfully achieved in all
atients. We performed CPVA by 8-mm catheter in 50
atients, and irrigated tip catheters were used in 49 patients.
ix weeks after the procedure, no patients in the ablation
roup were on AAD therapy. During follow-up, 85 patients
emained free from AT and discontinued ADT; warfarin
as also stopped in all but 3 having a mechanical mitral
alve. Recurrent symptomatic AF was documented by
able 2. Patient Characteristics
Characteristic
CPVA
(n  99)
ADT Group
(n  99) p Value
ge (yrs) 55  10 57  10 0.24
ender (M/F) 69/30 64/35 0.54
F episode/month 6  4 6  6 0.81
uration of AF (yrs) 6  4 6  6 0.81
A diameter (mm) 40  6 38  6 0.25
iabetes 5.1% 4% 1.00
ypercholesterolemia 17% 21% 0.59
ypertension 56% 57% 1.00
VEF (%) 60  8 61  6 0.49
tructural heart disease
Coronary artery disease 2% 2%
Valvular heart disease 3% 1% 0.22
Congenital heart disease 2% 1%
o. of previously ineffective
antiarrhythmic drugs
2  1 2  1 0.63
PVA  circumferential pulmonary vein ablation; LVEF  left ventricular ejection
raction; other abbreviations as in table 1.ranstelephonic ECG monitoring in 11 patients at the end if the blanking period; 5 were controlled by continuing
DT (flecainide in 4, sotalol in 1), whereas 6 required a
epeat ablation session (Fig. 3A). At this time, recovery of
onduction was documented in 5 left superior pulmonary
eins, 4 right superior pulmonary veins, 2 left inferior
ulmonary veins, and 1 left inferior pulmonary vein. After a
ouch-up of the previous ablation lines, 5 patients stopped
aving AF (mean post-repeat ablation follow-up 6 months).
he use of an irrigated tip catheter had a better outcome
han those ablated with an 8-mm catheter (p  0.03). After
blation, asymptomatic AF was observed in 3 patients who
therwise also reported symptomatic AF recurrences. In the
PVA group, the left atrial size was smaller at 12 months
fter (36  6 mm) than before (40  6 mm) ablation
p  0.01).
No serious complications were observed in any patient
ho underwent CPVA. Shortly after the procedure with an
-mm catheter, 1 patient with a mild apical hypertrophic
ardiomyopathy developed a spell transient ischemic attack,
hich resolved within a few seconds. Another patient who
erformed CPVA by the irrigated-tip catheter had a very
mall pericardial effusion not due to cardiac perforation,
hich otherwise did not require pericardiocentesis. Three
atients in the CPVA group developed post-ablation atrial
achycardia requiring activation mapping and ablation (Fig.
A). All patients underwent successful ablation after the
ndex procedure, and no further ATs were detected after 5,
, and 8 months of follow-up, respectively.
DT group. Of the 99 patients randomized to ADT, only
4 had their AF suppressed by a single AAD (amiodarone:
 12 of 33; flecainide: n  7 of 33; sotalol: n  5 of 33)
Fig. 3B) during the 12 months of follow-up. Of the 75
atients with AF recurrences, 20 (27%) had asymptomatic
pisodes; 49 were placed on combination therapy of 200 mg
f flecainide and 200 mg of amiodarone daily and 26 on 200
g of flecainide and 240 mg of sotalol; 11 patients were
ubsequently free from AF with the combination of flecain-
de and amiodarone; 22 patients still had AF on combina-
ion therapy although the arrhythmia was less frequent and
f short duration (amiodarone plus flecainide: n  16;
ecainide plus sotalol: n  6); the other 42 patients (7, 20,
nd 15 patients of the 3 subgroups, respectively) crossed
ver to CPVA (Fig. 3B). Overall, amiodarone was given to
1 patients as a single drug (33 patients) or in combination
28 patients). Amiodarone was as effective as flecainide and
otalol (35%, 19%, and 11%, respectively, p  0.11). No
hange in atrial size was noted in patients who remained in
R in the ADT group.
Significant adverse events leading to permanent drug
ithdrawal occurred in 23 patients. Pro-arrhythmia devel-
ped in 3 patients in the flecainide group (hypotensive wide
RS tachycardia in 2 patients and 1:1 atrial flutter in 1);
hyroid dysfunction occurred in 7 patients in the amioda-
one group requiring drug discontinuation; and sexual
mpairment in 11 patients in the sotalol group.
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CPVA Versus Drug Therapy in Paroxysmal AF December 5, 2006:2340–7rimary end point. By Kaplan-Meier analysis, 86% of
atients randomized to CPVA were AT-free at the end of
ollow-up as compared with the 22% of patients randomized
o ADT (p  0.001) (Fig. 3A); time 0 started at the end of
he 6-week blanking period.
ollow-up. Among the 99 patients in the ADT group, 42
nderwent CPVA after a mean of 5.8 months. At a mean of
.2 months of follow-up after crossover, 36 were free of
ecurrent AF in the absence of ADT, whereas AF was
resent in 6 (14%).
ospital admissions. Among patients assigned to CPVA,
summed up 24 hospital admissions for cardiovascular
auses, including repeat procedures. In the ADT group, 167
ardiovascular event-related hospital admissions occurred,
ot including the hospitalizations for crossover to CPVA (p
0.001). Monthly rhythm analysis in the NavX versus
ARTO subgroups showed sinus rhythm in 95% and 87%
t 1 year, respectively (p 0.08) (Fig. 4B), and in the 8-mm
ersus irrigated tip catheter groups 95% and 78% at 1 year,
espectively (p  0.03) (Fig. 4C). By monthly rhythm
nalysis that took into account also the outcome of the
econd procedure and for patients controlled with combined
igure 3. Flow of patients randomized to circumferential pulmonary vein
blation, stable sinus rhythm (SR) was obtained in 85 patients of whom 8
trial fibrillation (AF), 6 underwent a repeat procedure (REDO). Post-ab
uccessful re-do procedure. (B) Among patients randomized to ADT, 42
esign, AF was considered under control if the patient had no more thanherapy in ADT group, 93% of CPVA patients were free Prom atrial arrhythmias as compared with the 35% in the
DT group (Fig. 4D).
redictors of freedom from PAF. Among the clinical
arameters of age, gender, duration of AF (years), left atrial
ize, left ventricular ejection fraction (EF), whether or not
tructural heart disease was present, and treatment assign-
ent, CPVA was independently associated with SR main-
enance (hazard ratio 0.13, 95% confidence interval 0.07 to
.23, p  0.001). Further analysis revealed that EF (hazard
atio 1.08, 95% confidence interval 1.03 to 1.13, p 0.003),
ypertension (hazard ratio 2.31, 95% confidence interval
.34 to 3.97, p  0.003), and AF duration (hazard ratio
.03, 95% confidence interval 1.01 to 1.11, p  0.015) were
ndependent predictors of drug failure in the ADT group.
o independent predictors of AF recurrences were found in
he ablation group.
ISCUSSION
ain findings. The results of the present study demon-
trate that a single CPVA procedure is more effective than
DT in preventing AF relapses in selected patients with
ion (CPVA) and antiarrhythmic drug therapy (ADT) groups. (A) After
ped oral anticoagulant therapy (OAT). Of the 11 patients with recurrent
atrial tachyarrhythmia (AT) developed in only 3 patients, and all had a
nts crossed over to CPVA of whom only 6 had AF recurrence. By study
isode of AF in a 6-month period.ablat
2 stop
lationAF. Ablation strategy resulted in maintenance of SR at 1
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December 5, 2006:2340–7 CPVA Versus Drug Therapy in Paroxysmal AFear without the need for continuing ADT in 86% of
atients as documented by intensive daily transtelephonic
onitoring, whereas only 22% of patients in the ADT
roup remained in SR at 1 year. Maintenance of SR after
blation was associated with a reverse left atrial remodeling
nd with fewer adverse events and hospital admissions due
o cardiovascular causes.
F ablation strategy versus ADT: efficacy to prevent
AF. Fueled by dissatisfaction with pharmacologic therapy
nd the explosive development in catheter-based technolo-
ies, AF ablation has matured from a purely investigational
echnique to a preferred effective approach for treating AF
4–13). Currently, there are few studies comparing ablation
trategy with ADT in patients with PAF (4,11–13). We
rst reported in a non-randomized observational study the
triking superiority of AF ablation over ADT, which per-
isted up to 3 years after ablation (4). We also reported that
F ablation was associated with significantly lower mortal-
ty and adverse events compared with ADT in the long term
4). In the first pilot randomized study by Wazni et al. (11),
ho compared AF ablation with ADT, the authors, for the
igure 4. Outcomes in the APAF (Ablation for Paroxysmal Atrial Fibr
ircumferential pulmonary vein ablation (CPVA) needed only a single pr
ompared with the 22% of patients randomized to antiarrhythmic drug the
t the end of follow-up; time 0 started at the end of the 6-week blanking p
ARTO subgroups (95% and 87% at 1 year, respectively, p  0.08) an
espectively, p  0.03). (D) By monthly rhythm analysis that also took into
ombined therapy in ADT group, 93% of CPVA patients were free fromrst time, suggested that a strategy of using first-line tulmonary vein isolation among patients with initial epi-
odes of PAF may be superior to initial ADT at 1-year
ollow-up because 87% of ablated patients were AF-free
ompared with 37% of patients who received ADT. A more
ecent randomized trial by Stabile et al. (12) also suggests
hat AF ablation combined with ADT is superior to ADT
lone in preventing AF recurrences in patients with parox-
smal or persistent AF in whom ADT has already failed.
he results of the present study demonstrate a striking
uperiority of the ablation strategy over ADT. Ablation was
bout 2.5 times more effective than amiodarone (86% vs.
5%, respectively) in preventing AF recurrences in relatively
oung patients with PAF of long duration in the absence of
ajor complications. During a 12-month follow-up by
sing an intense transtelephonic monitoring, asymptomatic
F post-ablation was detected only in 3 patients in addition
o symptomatic AF recurrences, similarly to those reported
y Oral et al. (17); on the contrary, asymptomatic episodes
ere recorded in many patients (27%) in the ADT group.
he reports of these trials taken together indicate that AF
blation strategy indeed warrants consideration as first-line
n) trial. (A) By Kaplan-Meier analysis, 86% of patients randomized to
re and were atrial tachyarrhythmia (AT)-free at the end of follow-up as
ADT) (p  0.001) who did not require a second ADT and were AT-free
for both groups. (B and C) Monthly rhythm analysis in the NavX versus
the 8-mm versus irrigated tip catheter groups (95% and 78% at 1 year,
unt the outcome of the second procedure and for patients controlled with
as compared with the 35% in the ADT group. SR  sinus rhythm.illatio
ocedu
rapy (
eriod
d inherapy in selected patients in whom maintenance of SR is
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CPVA Versus Drug Therapy in Paroxysmal AF December 5, 2006:2340–7esired. In the present study, the rate of AF recurrence in
he ADT group was higher than that reported in previous
tudies but similar to that recently reported by Stabile et al.
12), and this in all probability was due to the same intensive
onitoring strategy performed in both studies. Consistent
ith prior reports of the effect of CPVA on left atrial size
18,19), there was a significant decrease in left atrial size
fter CPVA. This is an important issue in patients with
ncreased left atrial dimensions because this can further
revent atrial dilatation and disease progression. On the
ther hand, no left atrial remodeling was observed in the
roup of patients assigned to ADT.
F ablation strategy versus ADT: complications. ABLA-
ION STRATEGY. The efficacy of AF ablation strategy is
uperior to ADT, but the main concern and limitation of
ny ablative procedure is the potential occurrence of major
omplications. Unlike ADT, previous studies have shown
hat complications of CPVA typically result in only acute
nd not long-term morbidity with no case of death (4,5,12–
5,18). In the present study, a few transient complications
ccurred in the CPVA group. Patients who underwent
PVA by using tip-irrigated catheters were less likely to
ave AF recurrences than those ablated with an 8-mm
atheter. By introducing the modified CPVA approach that
ncludes additional posterior lines, the incidence of AT has
een lowered to 3.9% (15); in this study, we corroborate the
equirement of these linear lesions even if gaps in ablation
esions, either circular or linear, can be arrhythmogenic.
atients randomized to CPVA experienced less hospital
dmissions for cardiovascular causes than those randomized
o ADT. This can be explained by the superior efficacy of
PVA over ADT in suppressing AF and by the fewer
dverse events reported in the CPVA group.
DT. In symptomatic patients with a long history of AF,
sually ADT should be given for many years to prevent AF
ecurrences. Unfortunately, current AADs have many lim-
tations in terms of adverse effects, which in some cases may
e serious and may require drug discontinuation. Amioda-
one is well tolerated, but its chronic administration fre-
uently is associated with thyroid dysfunction, as observed
n 7 patients in our series, which may further aggravate
pisodes of PAF. In addition, the drug may induce pulmo-
ary toxicity, but our study was relatively short (1 year), and
id not address the potential for this serious adverse effect.
verall, in the present study, 23 patients (23%) discontin-
ed ADT because of adverse events, and these data compare
ell to the 11% to 28% reported in the AFFIRM (Atrial
ibrillation Follow-Up Investigation of Rhythm Manage-
ent), CTAF (Canadian Trial of Atrial Fibrillation), and
IAF (Rhythm or Rate Control in Atrial Fibrillation-
harmacological Intervention in Atrial Fibrillation Ran-
omised Trial) studies (2,20,21). Thus, although more than
ne-third of patients can be maintained in SR with 1 or
ore AAD, there is serious concern about the life-long usef these drugs to suppress AF. Proarrhythmic effects leadingo hemodynamic instability were observed in 3 patients in
he flecainide group (hypotensive wide QRS tachycardia in
and 1:1 atrial flutter in 1). Sexual dysfunction may be an
mportant limitation especially in young patients, and in our
eries this complication occurred in 11 young patients
uring sotalol therapy.
tudy limitations. The ablation procedures were per-
ormed in a single highly specialized center with extensive
xperience in CPVA in patients most of whom were
elatively young and healthy subjects. Therefore, these
esults cannot be generalized or applied to all AF patient
opulations. Although ablation was more effective than
DT at 1 year, maintenance of benefit and incidence of
dverse events over a much longer follow-up as compared
ith ADT remain unknown. Indeed, most patients will
equire ADT for many years, even decades, and thus would
e subject to longer potential adverse effects of the drugs. It
s possible that this “early” end point biases our results
oward ADT, for which longer-term adverse effects are a
oncern. Finally, although every effort was made to avoid
ny potential bias excluding patients with previous treat-
ent with amiodarone, flecainide, and sotalol, we cannot
ompletely exclude that in this study some patients also had
eceived these drugs over the past years. Even recognizing
he limitations of the study, we believe that our results
hallenge the notion that multiple and different AADs
hould be used life-long in patients with a long history of
AF.
onclusions. Among selected patients with a long history
f PAF, a single CPVA is more effective than ADT with 3
ADs widely used as single agents or in combination.
owever, before translating the results of this study into
linical practice, further multicenter randomized trials in
lder patients with more extensive heart disease with longer
ollow-up are required. Nevertheless, the results of our study
uggest that AF ablation strategy warrants consideration in
elected patients in whom ADT has already failed and
aintenance of SR is desired.
eprint requests and correspondence: Dr. Carlo Pappone, De-
artment of Arrhythmology, San Raffaele University Hospital, Via
lgettina 60, 20132—Milan, Italy. E-mail: carlo.pappone@hsr.it
r vincenzo.santinelli@hsr.it.
EFERENCES
1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary. A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the Euro-
pean Society of Cardiology Committee for Practice Guidelines and
Policy Conferences (Committee to Develop Guidelines for the Man-
agement of Patients With Atrial Fibrillation): developed in collabo-
ration with the North American Society of Pacing and Electrophysi-
ology. J Am Coll Cardiol 2001;38:1231–66.
2. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate
control and rhythm control in patients with atrial fibrillation. N Engl
J Med 2002;347:1825–33.3. Corley SD, Epstein AE, DiMarco JP, et al. Relationships between
sinus rhythm, treatment, and survival in the Atrial Fibrillation
11
1
1
1
1
1
1
1
1
2
2
2347JACC Vol. 48, No. 11, 2006 Pappone et al.
December 5, 2006:2340–7 CPVA Versus Drug Therapy in Paroxysmal AFFollow-Up Investigation of Rhythm Management (AFFIRM) study.
Circulation 2004;109:1509–13.
4. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and
quality of life after circumferential pulmonary vein ablation for atrial
fibrillation: outcomes from a controlled nonrandomized long-term
study. J Am Coll Cardiol 2003;42:185–97.
5. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denerva-
tion enhances long-term benefit after circumferential ablation for
paroxysmal atrial fibrillation. Circulation 2004;109:327–34.
6. Nademanee K, McKenzie J, Kosar E, et al. A new approach for
catheter ablation of atrial fibrillation: mapping of the electrophysi-
ologic substrate. J Am Coll Cardiol 2004;43:2044–53.
7. Oral H, Scharf C, Chugh A, et al. Catheter ablation for paroxysmal
atrial fibrillation: segmental pulmonary vein ostial ablation versus left
atrial ablation. Circulation 2003;108:2355–60.
8. Ouyang F, Bansch D, Ernst S, et al. Complete isolation of left atrium
surrounding the pulmonary veins: new insights from the double-Lasso
technique in paroxysmal atrial fibrillation. Circulation 2004;110:
2090–6.
9. Haissaguerre M, Hocini M, Sanders P, et al. Catheter ablation of
long-lasting persistent atrial fibrillation: clinical outcome and mecha-
nisms of subsequent arrhythmias. J Cardiovasc Electrophysiol 2005;
16:1138–47.
0. Pappone C, Santinelli V. Atrial fibrillation ablation: a realistic alter-
native to pharmacologic therapy. Nat Clin Pract Cardiovasc Med
2005;2:608–9.
1. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency
ablation vs antiarrhythmic drugs as first-line treatment of symptomatic
atrial fibrillation: a randomized trial. JAMA 2005;293:2634–40.
2. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment
in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure
Of Atrial Fibrillation Study). Eur Heart J 2006;27:216–21.
3. Oral H, Pappone C, Chugh A, et al. Circumferential pulmonary-vein
ablation for chronic atrial fibrillation. N Engl J Med 2006;354:934–
94.
4. Pappone C, Santinelli V. The who, what, why, and how-to guide for
circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol
2004;15:1226–30.
5. Pappone C, Manguso F, Vicedomini G, et al. Prevention of iatrogenic
atrial tachycardia after ablation of atrial fibrillation: a prospective
randomized study comparing circumferential pulmonary vein ablation
with a modified approach. Circulation 2004;110:3036–42.
6. The AFFIRM First Antiarrhythmic Drug Substudy Investigators.
Maintenance of sinus rhythm in patients with atrial fibrillation: an
AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol
2003;42:20–9.
7. Oral H, Veerareddy S, Good E, et al. Prevalence of asymptomatic
recurrences of atrial fibrillation after successful radiofrequency catheter
ablation. J Cardiovasc Electrophysiol 2004;15:920–4.
8. Pappone C, Oreto G, Rosanio S, et al. Atrial electroanatomic
remodeling after circumferential radiofrequency pulmonary vein abla-
tion: efficacy of an anatomic approach in a large cohort of patients with
atrial fibrillation. Circulation 2001;104:2539–44.
9. Lemola K, Sneider M, Desjardins B, et al. Effects of left atrial ablation
of atrial fibrillation on size of the left atrium and pulmonary veins.
Heart Rhythm 2004;1:576–81.
0. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence
of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators.
N Engl J Med 2000;342:913–20.
1. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial
fibrillation—Pharmacological Intervention in Atrial Fibrillation
(PIAF): a randomised trial. Lancet 2000;356:1789–94.
